News
ITCI
--
0.00%
--
Why did Intra-Cellular Therapies Stock Jump today? Demand for antipsychotic drug
Intra-Cellular Therapies (ITCI +10.0%) has bounced back from a one-month low as several Wall Street analysts pointed to the strong performance of the company’s antipsychotic medication, CAPLYTA. The uptick in
Seekingalpha · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 2d ago
34 Stocks Moving In Friday's Mid-Day Session
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday.
Benzinga · 2d ago
Intra-Cellular Therapies gains amid insider selling
Intra-Cellular Therapies (ITCI +10.6%) has gained more than a tenth even after its Chief Medical Officer Suresh Durgam declared the sale of more than a fifth of his holdings at
Seekingalpha · 2d ago
Penbrook Management LLC Buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Sells ...
New York, NY, based Investment company Penbrook Management LLC (Current Portfolio) buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Chevron Corp, Intra-Cellular Therapies Inc, sells Nuance Communications Inc, Aspen Group Inc, The One Group Hosp...
GuruFocus.com · 01/10 22:38
Intra-Cellular Therapies raises $400M via stock offering
Intra-Cellular Therapies (NASDAQ:ITCI) has priced its public offering of 9,523,810 common shares at $42.00/share, for expected gross proceeds of $400M. Underwriters' over-allotment is an additional 1,428,571 shares. Closing date is
Seekingalpha · 01/05 05:45
Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing ...
GlobeNewswire · 01/05 03:05
Hot Stocks: UAA upgrade; FL downgrade; AGFY partnership; ITCI stock offering
Analyst comments represented a key theme in Tuesday's midday trading, with the athletic apparel space taking the spotlight. A bullish comment gave a lift to Under Armour (NYSE:UAA), while Foot
Seekingalpha · 01/04 18:31
The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 01/04 13:11
IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med
Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of
Benzinga · 01/04 11:27
5 Stocks To Watch For January 4, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% t...
Benzinga · 01/04 10:05
Company News for Dec 21, 2021
Zacks.com · 01/04 02:43
TBLA, ITCI and GOSS among after hour movers
Gainers: WISeKey International Holding  (NASDAQ:WKEY) +11%. Taboola.com  (NASDAQ:TBLA) +5%. Kingsoft Cloud Holdings Limited (NASDAQ:KC) +4%. Jiayin Group  (NASDAQ:JFIN) +3%. Intevac  (NASDAQ:IVAC) +3%. Losers: Intra-Cellular Therapies  (NASDAQ:ITCI) -8%. G...
Seekingalpha · 01/03 23:01
Intra-Cellular Therapies slumps 12% amid launch of $400M common stock offering
Intra-Cellular Therapies (NASDAQ:ITCI) began a $400M common stock offering. The company intends to grant the underwriters a 30-day option to buy up to an additional 15% of the shares sold
Seekingalpha · 01/03 21:05
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has ...
GlobeNewswire · 01/03 21:01
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon ...
GlobeNewswire · 01/03 13:00
BRIEF-Intra-Cellular Therapies Entered Amendment To Agreement Between Siegfried Evionnaz And Co's Unit
reuters.com · 12/29/2021 21:18
Advisors' Inner Circle Fund III Buys SPDR Biotech ETF, Scientific Games Corp, Silvergate ...
Investment company Advisors' Inner Circle Fund III (Current Portfolio) buys SPDR Biotech ETF, Scientific Games Corp, Silvergate Capital Corp, Boot Barn Holdings Inc, UMH Properties Inc, sells Squarespace Inc, Arena Pharmaceuticals Inc, Vimeo Inc, Singular ...
GuruFocus.com · 12/28/2021 04:38
3 “Strong Buy” Stocks Showing Monster Growth
The past 20 months have been good for growth stocks, to say the least. In that time, the S&P 500 just about doubled, while the NASDAQ has done even better, gaining 125%. Corporate earnings strongly rebounded this year, post-COVID, and the government’s stim...
TipRanks · 12/23/2021 15:32
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about INTRA CELLULAR through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.